CLOs on the Move

Ratio Therapeutics

www.ratiotx.com

 
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ISTA Pharmaceuticals

ISTA Pharmaceuticals, Inc. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Savara Pharmaceuticals

Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Tetragenex Pharmaceuticals

Tetragenex Pharmaceuticals is a Syosset, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProTom International

Protoms Radiance 330 Proton Therapy System is compact, customizable, and has the industrys fastest return on investment.

Zura Bio Limited

Zura Bio is a clinical stage biotechnology company focused on developing ZB 168, an anti IL7Rα inhibitor, for the treatment of alopecia areata and other inflammatory diseases.